Cargando…

Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score

Background: Clinical-pathological factors and 21-gene recurrence score (RS) influence adjuvant chemotherapy (ACT) decision for early breast cancer patients. We investigated the decision-making of ACT in patients with discordant risk classifications of clinical-pathological factors and RS. Methods: P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Weiqi, Lin, Lin, Fei, Xiaochun, Chen, Xiaosong, Shen, Kunwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066016/ https://www.ncbi.nlm.nih.gov/pubmed/32201521 http://dx.doi.org/10.7150/jca.38976

Ejemplares similares

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
por: Yu, Jing, et al.
Publicado: (2021)

Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26–30
por: Yu, Jing, et al.
Publicado: (2020)

Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component
por: Zeng, Yufei, et al.
Publicado: (2020)

Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
por: Yu, Jing, et al.
Publicado: (2020)

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2020)

Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study
por: Wang, Wei, et al.
Publicado: (2018)

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
por: Wu, Jiayi, et al.
Publicado: (2017)

Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis
por: Lu, Yujie, et al.
Publicado: (2021)

Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2021)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
por: Hong, Jin, et al.
Publicado: (2021)

Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study
por: Wu, Jiayi, et al.
Publicado: (2020)

Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis
por: Wu, Chenghui, et al.
Publicado: (2023)

Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer
por: Gao, Weiqi, et al.
Publicado: (2019)

Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer
por: Wu, San-Gang, et al.
Publicado: (2019)

Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2021)

Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients
por: Tong, Yiwei, et al.
Publicado: (2022)

Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases
por: Chen, Wei-Rong, et al.
Publicado: (2019)

Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients
por: Cai, Lifen, et al.
Publicado: (2020)

A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study
por: Yu, Jing, et al.
Publicado: (2021)

Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample
por: Zhu, Siji, et al.
Publicado: (2019)

Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age
por: Bernhardt, Sarah M., et al.
Publicado: (2020)

Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher
por: Ma, Sung Jun, et al.
Publicado: (2020)

Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases
por: Zhu, Siji, et al.
Publicado: (2023)

21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients
por: Zhu, Yifei, et al.
Publicado: (2021)

Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery
por: Hong, Jin, et al.
Publicado: (2021)

Geriatric functional assessment for decision-making on adjuvant chemotherapy in older colon cancer patients
por: Bang, Hyun Jin, et al.
Publicado: (2022)

Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals
por: Martínez del Prado, Purificación, et al.
Publicado: (2018)

Impact of pathological response after neoadjuvant chemotherapy on adjuvant therapy decisions and patient outcomes in gastrointestinal cancers
por: Bhalla, Sheena, et al.
Publicado: (2021)

Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment
por: Zhu, Siji, et al.
Publicado: (2021)

Prognostic Nomogram for Postoperative Hypopharyngeal Squamous Cell Carcinoma to Assist Decision Making for Adjuvant Chemotherapy
por: Zhang, Di, et al.
Publicado: (2022)

Making adjuvant therapy decisions with uncertain data
por: Gyawali, B, et al.
Publicado: (2019)

Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
por: Soliman, Hatem, et al.
Publicado: (2020)

Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30
por: Park, Seho, et al.
Publicado: (2019)

Prognostic Nomogram for Early Gastric Cancer After Surgery to Assist Decision-Making for Treatment With Adjuvant Chemotherapy
por: Zhang, Chao, et al.
Publicado: (2022)

Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients
por: Fang, Yan, et al.
Publicado: (2020)

A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer
por: Lin, Caijin, et al.
Publicado: (2020)

Couple’s concordance and discordance in household decision-making and married women’s use of modern contraceptives in Bangladesh
por: Uddin, Jalal, et al.
Publicado: (2017)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qlpt59soi0gunhp9j4u585cof0